Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS
January 27th 2024The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.
Read More
New MG Research Focuses on More Tailored Treatment, Bibliometric Analysis Finds
January 27th 2024The data search of Web of Science Core Collection, spanning 2003 to 2022, identified various prospective directions in myasthenia gravis (MG) research, including in personalized treatment, subtype-based treatment, and novel immunotherapeutic strategies.
Read More
Impact of a Pharmacist-Managed TOC Clinic on Diabetes Outcomes Following Hospitalization
January 27th 2024While the clinic did not significantly reduce hospital readmission rates for patients with diabetes, it was able to decrease the time to follow-up and improve long-term diabetes outcomes following hospitalization.
Read More
Health Equity and Access Weekly Roundup: January 27, 2024
January 27th 2024The Center on Health Equity and Access delivers current updates, highlights breakthroughs in research, and ongoing endeavors committed to addressing healthcare inequalities and improving universal access to exceptional health care.
Read More
Contributor: It’s About Time to Realize the Full Potential of Data in Health Care
January 26th 2024Promoting health equity isn’t only about consideration of underlying health risks; it’s also about using that data to inform population care as well as give clinicians and their teams more time with the patient in front of them.
Read More
US women in low-income regions are experiencing a steep increase in cervical cancer diagnosis and death despite medical improvements; a Senate committee launches an assisted living examination, its first hearing on the industry in 2 decades; the CDC urges health care providers to be alert for patients who have fever, rashes, an traveled abroad following reports of 23 measles cases since December 1.
Read More
Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS
January 26th 2024Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).
Read More
Tofacitinib as AA Treatment Has High Drug Survival Rates, Manageable Side Effects
January 25th 2024A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.
Read More
Female Patients Less Likely to Receive Guideline-Directed HFrEF Therapies vs Males
January 25th 2024A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients compared with male patients.
Read More
What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link
January 25th 2024A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.
Read More
DMD Guidance Could Benefit From Update, Experts Say
January 24th 2024MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Read More
Extended Study Shows Consistent Safety, Efficacy in Complex Mental Health Treatment
January 24th 2024Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder.
Read More
Similar Risk of Death Between Patients With HFimpEF, LVEF Above 40% in DELIVER Trial
January 24th 2024An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).
Read More